Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deciphering the molecular mechanism of FLT3 resistance mutations.

The FEBS journal - 1 Aug 2020

Georgoulia Panagiota S, Bjelic Sinisa, Friedman Ran

Abstract excerpt

FMS-like tyrosine kinase 3 (FLT3) has been found to be mutated in ~ 30% of acute myeloid leukaemia patients. Small-molecule inhibitors targeting FLT3 that are currently approved or still undergoing clinical trials are subject to drug resistance due to FLT3 mutations. How these mutations lead to drug resistance is hitherto poorly understood. Herein, we studied the molecular mechanism of the drug resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzothiazoles
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Phenylurea Compounds

Share to Protein Conformation

Share to Protein Kinase Inhibitors

Share to Pyrroles

Source

Identifiers

PMID: 31943770
DOI: 10.1111/febs.15209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering the molecular mechanism of FLT3 resistance mutations.PMID 31943770Read ↗

The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.Semantic proximity Read ↗

Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.Semantic proximity Read ↗

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.Semantic proximity Read ↗

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.Semantic proximity Read ↗

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.Semantic proximity Read ↗

Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase.Semantic proximity Read ↗

Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.Semantic proximity Read ↗

Revealing acquired resistance mechanisms of kinase-targeted drugs using an on-the-fly, function-site interaction fingerprint approachSemantic proximity Read ↗

Deciphering the mechanism of HM43239 inhibiting the mutant F691L resistant to gilteritinib in FMS-like tyrosine kinase 3.Semantic proximity Read ↗

The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical StudySemantic proximity Read ↗

Molecular Dynamics Studies on D835N Mutation in FLT3—Its Impact on FLT3 Protein StructureSemantic proximity Read ↗

Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational DynamicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.